We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
John Alam is President and CEO of EIP Pharma.
Until May 2014, he was therapeutic area head for diseases of aging within Sanofi R&D. In that role he led on a global basis R&D activities at Sanofi directed at Alzheimer’s disease, as well as number of other age-related diseases.
Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and EVP, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. And, from 1991 to 1997, while at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a).
John has a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and post-doctoral fellowship at Dana-Farber Cancer Institute.
This speaker's sessions: